Human Metabolome Technologies (TSE:6090) Short-Term Debt: 円100 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6090 Human Metabolome Technologies Inc TSE:6090
54 GF Score
Price 円600.00
GF Value 円798.94
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Human Metabolome Technologies Short-Term Debt?

Human Metabolome Technologies TSE:6090 +0.33% 54 Short-Term Debt is 円100 Mil as of Dec. 2025. GuruFocus rates TSE:6090 with a GF Score™ of 54/100 and a GF Value™ of 円798.94 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Human Metabolome Technologies's Short-Term Debt for the quarter that ended in Dec. 2025 was 円100 Mil.

Human Metabolome Technologies's quarterly Short-Term Debt stayed the same from Jun. 2025 (円100 Mil) to Sep. 2025 (円100 Mil) and stayed the same from Sep. 2025 (円100 Mil) to Dec. 2025 (円100 Mil).

Human Metabolome Technologies's annual Short-Term Debt stayed the same from Jun. 2022 (円200 Mil) to Jun. 2023 (円200 Mil) and stayed the same from Jun. 2023 (円200 Mil) to Jun. 2024 (円200 Mil).

Human Metabolome Technologies Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Human Metabolome Technologies Short-Term Debt Related Terms

Human Metabolome Technologies Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Human Metabolome Technologies's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Human Metabolome Technologies Short-Term Debt Chart

Human Metabolome Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Jun20 Jun21 Jun22 Jun23 Jun24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 100.00 200.00 200.00 200.00

Human Metabolome Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 200.00 100.00 100.00 100.00 100.00
TSE:6090
54GF Score
Human Metabolome Technologies Inc TSE:6090
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of 円100 Mil mean?
Human Metabolome Technologies (TSE:6090) has a Short-Term Debt of 円100 Mil as of Dec. 2025.
Is Human Metabolome Technologies' Short-Term Debt too high?
Human Metabolome Technologies' current Short-Term Debt is 円100 Mil. Overall, Human Metabolome Technologies has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Short-Term Debt compare to TMO and DHR?
Human Metabolome Technologies' Short-Term Debt of 円100 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Human Metabolome Technologies's current Short-Term Debt is 円100 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円798.94, compared to a current price of 円600.00 — trading 24.9% below its estimated fair value. The current Short-Term Debt is 円100 Mil. Human Metabolome Technologies' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Short-Term Debt is 円100 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?

Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued. The current stock price of 円600.00 is trading 24.9% below its estimated GF Value™ of 円798.94. GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.

Key valuation signals for TSE:6090:

  • Short-Term Debt: 円100 Mil
  • GF Value™: 円798.94 vs. price of 円600.00 (24.9% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Human Metabolome Technologies Business Description

Address Yamagata Prefecture Kakuganji Water 246-2, Tsuruoka, JPN, 997-0052
Human Metabolome Technologies Inc is involved in the search and diagnosis of biomarkers and commercialization in the field of drug development.
54GF Score

Get the complete analysis for TSE:6090

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円600.00
Price
円798.94
GF Value